A recent study has uncovered a significant association between a commonly prescribed blood pressure drug and an increased risk of serious kidney issues in individuals with type 2 diabetes.
Key Insights
Dihydropyridine calcium-channel blockers (DCCBs) have been linked to a 33% higher risk of major adverse kidney events in people with type 2 diabetes. Notably, this increased risk persists even when patients are taking kidney-protective medications such as RAS and SGLT2 inhibitors. The study's findings are based on the analysis of health data from over 31,000 adults with type 2 diabetes between 2016 and 2021.










